Sponsor Dossier
Accord Healthcare
Sponsor Dossier for Accord Healthcare. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACCOZOLE
- Brand: ACICLOVIR
- Brand: ANASTROZOLE
- Brand: Anidulafungin
- Brand: APO-Tadalafil
- Brand: ARIPADOL
- Brand: ARIPIPRAZOLE
- Brand: ARX-GLIMEPIRIDE
- Device (sponsor): Subcutaneous/intramuscular injection set, medicated
About
Accord Healthcare is an Australian Private Company with ABN 49110502513, registered in Victoria. The entity status is Active.
Portfolio
Accord Healthcare has 145 brands on the ARTG, of which 73 are indexable and 62 carry a Product Information document. 41 brands are PBS-listed, 2 have a PBAC outcome on record, and 7 have an AusPAR on record. Notable brands include ACCOZOLE, ACICLOVIR, ANASTROZOLE, Anidulafungin, APO-Tadalafil, ARIPADOL, ARIPIPRAZOLE, ARX-GLIMEPIRIDE, ARX-LINAGLIPTIN, ARX-Mycophenolate, AZACCORD, AZACITIDINE.
Therapeutic focus
— Oncology: 40 brands — Endocrinology: 20 brands — Cardiology: 19 brands — Neurology: 16 brands — Psychiatry: 10 brands — Musculoskeletal: 7 brands — Dermatology: 5 brands — Infectious Disease: 4 brands — Respiratory: 4 brands — Immunology: 4 brands — Renal: 4 brands — Other: 3 brands — Pain Management: 3 brands — Haematology: 3 brands — Gastroenterology: 2 brands — Reproductive Health: 1 brand
PBS footprint
41 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2022-03-01, across 2 brands with a PBAC outcome on record. The latest AusPAR is 2026-04-21, across 7 brands with an AusPAR on record.